Two-Photon Research
Innovating Semiconductors using Photons

In a world predominantly governed by modern technology and automation, semiconductor electronics play a major role in everyday life. Advancements in semiconductor technology coupled with extensive R&D are expanding its applicability across various fields like telecommunications, consumer electronics, and lighting systems. However, COVID-19 and the recent semiconductor shortage have severely strained the global supply of semiconductor chips, causing many companies to limit their research capabilities to a handful of options.

Two-Photon Research (TPR) Inc. flips the script by creating numerous semiconductor-based innovations to help companies in their research endeavors. TPR explores many approaches to using photons and creates a wide range of solutions for various applications, from molecular diagnostics to futuristic color displays. Its specialties include light emitting devices, Aptamer Molecular Photonic Beacon™, and Gallium-Nitride (Ga- N) and Germanium-Tin (Ge-Sn) semiconductors.

“TPR covers the R&D of photonics, optics, pathogen diagnostics, and precision motion systems. We hold a wide range of international patents in our portfolio,” says Najeeb Khalid, CEO of Two-Photon Research.

TPR’s Ge-Sn and Ga-N alloys play a pivotal role in the semiconductor market. Ge-Sn is a new material developed by TPR in collaboration with leading universities, enabling a semiconductor band gap in the midinfrared range of around three microns (0.003mm).

While the material has proven applications across different industrial processes, Ge-Sn is a relatively nascent technology that can be licensed to any entity that requires integrated optics. The most vital part of Ge-Sn is its fabrication process, which is similar to a conventional siliconbased complementary metal-oxide semiconductor (CMOS), ensuring the new emitters and detectors are always compatible with existing devices. A Ge-Sn CMOS eliminates nearly 200 wafer layers during the fabrication of a multi-core processor to empower inter-processor communication links via photonics while reducing the space devoted to communication tracks amid the cores and delivering light-speed communication between systems. Currently, TPR has recorded speeds of up to four Gb/s with the potential of pushing it to 100Gb/s.

Through its Ga-N, TPR has developed flowless GaN on Sapphire templates for GaN devices.

Concurrently, TPR is a pivotal player in bio-photonics R&D, developing biomarkers that link biochemistry and physics to send molecule-specific detection alerts to researchers and enabling photonic techniques and quantum mechanics to measure and announce test results at markedly decreased costs. TPR’s COVID-19 and heart disease Troponin tests that detect relevant biomarkers within 10 seconds are key examples of its bio-photonics prowess. Through its cancer biomarker tests, users can measure different kinds of malignant cells (if the required biomarker is readily available). It can turn any biomarker into a test within 60 days, expanding the horizons of diagnostics to a new dimension that decentralizes testing processes by reducing reliance on laboratories. Presently, TPR offers Troponin and COVID-19 tests with assessments for more biomarkers found in lung cancer, breast cancer, and dengue fever in its pipeline.

An extraordinary milestone that perfectly highlights TPR’s innovationbacked success is the rapid approval of its U.S. patent, which was awarded within six hours of filing compared to the usual one to three years. TPR aims to continue driving the semiconductor industry forward with its exceptional R&D-led innovation for the display and bio-photonics sectors.